Elisrasib: Next-Gen KRAS G12C Inhibitor Shows Promise in Advanced Lung Cancer Treatment

SAN DIEGO—A next-generation KRAS G12C inhibitor called elisrasib has shown promising response rates in patients with advanced non-small cell lung cancer (NSCLC) whose tumors harbor the KRAS G12C mutation, according to results presented at the American Association for Cancer Research (AACR) Annual Meeting 2026. The findings offer new hope for patients whose disease has progressed after prior therapies, including those who have already been treated with first-generation KRAS G12C inhibitors.

Targeting a Common but Challenging Mutation

The KRAS G12C mutation is the most common KRAS alteration in NSCLC, accounting for approximately 13% of cases. Until recently, KRAS mutations were considered “undruggable” due to their smooth surface and lack of obvious binding pockets for small-molecule inhibitors. However, the development of first-generation KRAS G12C inhibitors—such as sotorasib (Lumakras) and adagrasib (Krazati)—marked a breakthrough, offering targeted treatment options for patients with this mutation. These drugs work by irreversibly binding to the mutant KRAS protein in its inactive state, preventing it from driving cancer cell growth.

Despite their clinical benefits, first-generation inhibitors have limitations. Many patients develop resistance over time, and the drugs may not fully suppress tumor growth in all cases. Elisrasib, a next-generation KRAS G12C inhibitor, was designed to address these challenges by improving target engagement and overcoming mechanisms of resistance, including growth factor-induced nucleotide exchange.

Promising Results in Phase 1/2 Trial

The results presented at AACR 2026 come from an ongoing phase 1/2 clinical trial evaluating elisrasib in patients with locally advanced or metastatic NSCLC whose disease progressed after prior therapies. The study included two key patient groups: those who had not previously received a KRAS G12C inhibitor and those whose disease had progressed despite treatment with first-generation inhibitors.

Byoung Chul Cho, MD, PhD, professor in the Division of Medical Oncology at the Yonsei Cancer Center of Yonsei University College of Medicine in Korea, presented the findings. According to Dr. Cho, elisrasib demonstrated “robust and durable efficacy” in both patient groups, with responses observed even in those who had developed resistance to earlier KRAS G12C inhibitors. The drug also showed a “favorable tolerability” profile, with side effects comparable to those of first-generation inhibitors.

In the phase 1a portion of the trial, 42 patients with advanced KRAS G12C-mutant cancers—including NSCLC, colorectal cancer, and pancreatic ductal adenocarcinoma—received elisrasib at various doses. The primary endpoints were safety, tolerability, and determination of the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). No dose-limiting toxicities were observed, and the MTD was not reached. The RP2D was established at 600 mg based on pharmacokinetic data.

Among 34 evaluable patients with KRAS G12C inhibitor-naive disease, the objective response rate (ORR) was 73.5%. The disease control rate (DCR) was even higher at 97.1%, indicating that the vast majority of patients experienced at least stabilization of their disease. The estimated 6-month duration of response (DOR) was 78.4%, and the 6-month progression-free survival (PFS) rate was 68.6%. These results suggest that elisrasib may provide more durable benefits than first-generation inhibitors.

Mechanism of Action and Potential Advantages

Elisrasib was specifically designed to improve upon the limitations of first-generation KRAS G12C inhibitors. Unlike its predecessors, which bind to the inactive state of the KRAS protein, elisrasib is engineered for faster and stronger target engagement. This enhanced binding affinity may help overcome resistance mechanisms, such as the reactivation of KRAS signaling through growth factor pathways.

Dr. Cho emphasized the significance of these design improvements in an AACR press release: Research is now focused on next-generation inhibitors aiming for safer, more effective, and longer-lasting results. These new treatments may address challenges such as brain metastases and resistance to earlier drugs, potentially improving outcomes and redefining care for lung cancer patients with KRAS G12C mutations.

The potential to overcome resistance is particularly important for patients with NSCLC, where KRAS G12C mutations are prevalent. Resistance to first-generation inhibitors often develops through secondary mutations or alternative signaling pathways that reactivate KRAS. Elisrasib’s improved target engagement may help delay or prevent these resistance mechanisms, offering a more durable treatment option.

Safety and Tolerability

The safety profile of elisrasib appears to be consistent with that of first-generation KRAS G12C inhibitors. In the phase 1a trial, 16.7% of patients experienced grade 3 treatment-related adverse events (TRAEs), primarily elevated serum markers or nausea. No grade 4 or 5 TRAEs were reported, and the drug was generally well tolerated. These findings suggest that elisrasib could be a viable option for patients who may not tolerate more toxic therapies.

Broader Implications for KRAS-Mutant Cancers

While the AACR 2026 presentation focused on NSCLC, elisrasib is also being evaluated in other KRAS G12C-mutant cancers, including colorectal cancer and pancreatic ductal adenocarcinoma. In the phase 1a trial, responses were observed across all three cancer types, with ORRs of 66.7% in colorectal cancer and 75.0% in pancreatic cancer among KRAS G12C inhibitor-naive patients. These results suggest that elisrasib could have broader applications beyond lung cancer.

The development of elisrasib reflects a growing trend in oncology: the refinement of targeted therapies to address the limitations of earlier treatments. As researchers gain a deeper understanding of resistance mechanisms, next-generation inhibitors like elisrasib may offer more effective and durable options for patients with KRAS-mutant cancers.

Next Steps and Future Research

The phase 1/2 trial of elisrasib is ongoing, with further data expected to clarify its long-term efficacy and safety. Future research may also explore combination therapies, such as pairing elisrasib with immune checkpoint inhibitors or other targeted agents, to enhance its antitumor effects. Studies are needed to determine whether elisrasib can effectively treat brain metastases, a common and challenging complication in NSCLC.

For patients with KRAS G12C-mutant NSCLC, the emergence of next-generation inhibitors like elisrasib represents a significant advancement. While first-generation inhibitors have already transformed the treatment landscape, elisrasib and similar drugs may offer improved outcomes for those who develop resistance or do not respond to existing therapies. As clinical trials progress, elisrasib could become a new standard of care for this patient population.

The AACR Annual Meeting 2026, held from April 17 to 22 in San Diego, continues to serve as a platform for presenting cutting-edge research in cancer treatment. The results for elisrasib underscore the rapid pace of innovation in targeted therapies and the ongoing efforts to address unmet needs in cancer care.